Tenofovir disoproxil fumaratevs adefovir dipivoxil in Chinese treatment naive patients with chronic hepatitis B for 48 weeks：a randomized, double-blinded, controlled study

Song Yang,Huichun Xing,Yanyan Yu,Jianbiao Cao,Liang Chen,Wei Lu,Xu Li,Xinyue Chen,Yongping Yang,Maorong Wang,Baosheng Shen,Jun Cheng

DOI: https://doi.org/10.3877/cma.j.issn.1674-1358.2016.04.001

2016-01-01

Abstract:Objective To evaluate the efifcacy and safety proifles of tenofovir disoproxil fumarate (TDF) vs adefovir dipivoxil (ADV) for Chinese patients with chronic hepatitis B (CHB).Methods In this randomized, double-blind, controlled study, patients with CHB received TDF or ADV (ratio for 1︰1) once daily for 48 weeks were assigned, randomly. The primary efficacy end point was plasma HBV DNA level < 20 IU/ml at week 48. The levels of HBV DNA decrease, ratios of ALT normalization, HBsAg loss and seroconversion and HBeAg loss and seroconversion, while the adverse events and adverse effects were also compared between patients in TDF group and ADV group.Results Total of 267 patients were enrolled, among whom, there were 141 patients in TDF group and 139 patients in ADV group. The baseline characteristics were comparable between the two groups (P all > 0.05). At week 48, virological responses occurred in more HBeAg positive patients with TDF treatment than patients with ADV treatment (55.3%vs. 20.0%;χ2= 20.750,P < 0.001) and in more HBeAg negative patients with TDF treatment than patients receiving ADV treatment (86.2%vs. 62.7%;χ2= 20.750,P = 0.003). There were no signiifcant difference in ratio of ALT normalization in both HBeAg positive (84.5%vs. 80.5%;χ2= 0.406,P = 0.524) and negative groups (84.2%vs. 80.7%;χ2= 0.243,P = 0.622). In HBeAg positive group, there were no significant difference in ratio of HBeAg loss (5.6%vs. 12.8%;χ2= 2.335,P = 0.126) and HBsAg loss (1.4%vs. 3.8%;χ2= 0.182,P = 0.670). No case in HBeAg negative group lost HBsAg after 48 weeks therapy. Safety proifles including incidence of adverse events and adverse effects were compared between TDF and ADV groups with no significant difference (P all > 0.05).Conclusions Among Chinese CHB patients with HBeAg positive and negative, TDF had superior antiviral efifcacy with a similar safety proifle compared with ADV through 48 weeks.